Skip to main content
OpenTrials
Completed

NCT Number: NCT00256165

REST Study: Left Ventricular Regression European Study

The purpose of this study is to obtain data regarding the left ventricular mass (LVM) regression 6 months after the implant of an SJM Epic™ and SJM Epic™ Supra valve by comparing LVM regression measured with magnetic resonance imaging (MRI) to LVM regression measured with echocardiography (2-dimensional [2D] mandatory; 3-dimensional [3D] in sites where the technology is available).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Städtlishes Klinikum Braunschweig

Braunschweig, 38126, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient requires, for the first time, isolated aortic valve replacement due to aortic stenosis or mixed aortic stenosis disease etiology when aortic stenosis is predominant and aortic regurgitation is mild.
  • Patient is of legal age in the host country.
  • Patient (or legal guardian) has signed a study specific informed consent form

Exclusion criteria

  • Patient was previously operated on with any heart surgery including heart valve replacement or coronary artery bypass graft (CABG); or underwent any form of myocardial revascularization in the past (including stents), etc.
  • Patient requires any concomitant heart surgery other than the isolated native aortic heart valve replacement and concomitant ascending aortic replacement (e.g not allowed are: multiple valve replacements or concomitant CABG, pacemaker insertions, or severe septal hypertrophy needing surgical excision, etc.)
  • Patient has unstable angina
  • Patient is in New York Heart Association functional class IV
  • Patient has significant abnormality in wall motion
  • Patient is affected by active endocarditis.
  • Patient has a cardiac pacemaker or automatic implanted cardiac defibrillator
  • Patient is affected by acute aortic dissection.
  • Patient is in chronic and persistent atrial fibrillation
  • Patient receives hemodialysis therapy
  • Patient has a medical condition which contraindicates implantation of the SJM Epic and Epic™ Supra Porcine Bioprosthetic Heart Valve (e.g. renal failure or abnormal calcium metabolism).
  • Patient has aneurysmal clips or carotid artery vascular stents
  • Patient has a neurostimulator
  • Patient has an implanted or external drug infusion device (e.g. insulin pump)
  • Patient has a bone growth/fusion stimulator
  • Patient has a cochlear, otologic, or ear implant
  • Patients with severe claustrophobia in which medical sedation is contraindicated or unable to resolve anxiety sufficiently
  • Patients with ocular foreign body (e.g. metal shavings)
  • Patient is pregnant or nursing

Treatment and study plan

Tissue valve

Device

Aortic valve replacement

Primary outcomes

  1. The comparison of left ventricular mass index (LVMI) at 6 months between echocardiogram (echo) and MRI in patients implanted with an Epic valve

    Time frame: At 6 months

Sponsors and collaborators

Lead sponsor

Abbott Medical Devices

Industry

Registry information

Official study title

Left Ventricular Regression European Study

Important dates

Study start
2006
Primary completion
2008
Study completion
2008
First posted
Nov 21, 2005
Registry last updated
Feb 4, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.